Arthritis Research & Therapy最新文献

{"title":"Risk of gastrointestinal cancers in patients with primary Sjögren's syndrome in Korea: a nationwide retrospective cohort study.","authors":"Soonsu Shin, Min-Ho Kim, Chang-Mo Oh, Dosang Cho, Jae-Hong Ryoo","doi":"10.1186/s13075-025-03696-4","DOIUrl":"https://doi.org/10.1186/s13075-025-03696-4","url":null,"abstract":"<p><strong>Background: </strong>The risk of non-Hodgkin's lymphoma in patients with primary Sjögren's syndrome (pSS) is well established. However, the association between pSS and the risk of gastrointestinal cancers remains underexplored. This study aims to assess the risk of gastrointestinal cancers in pSS patients in Korea compared with the general population.</p><p><strong>Methods: </strong>We included 320,082 participants from National Health Insurance Service-National Sample Cohort (NHIS-NSC) database. Of these, there were 850 patients with pSS and 319,232 in the non-pSS group. All participants were followed-up until 2019 or the development of gastrointestinal cancers, whichever occurred first. Hazard ratio (HR) and 95% confidence intervals (95% CI) for gastrointestinal cancers were calculated by multivariable Cox proportional hazards models.</p><p><strong>Results: </strong>Compared with the non-pSS group, patients with pSS had a higher risk of developing all gastrointestinal cancers, but the association did not reach statistical significance (adjusted HR: 1.240, 95% CI: 0.990-1.543). Site-specific analyses showed that pSS patients had a higher risk of colorectal cancer (adjusted HR: 1.597, 95% CI: 1.122-2.273) and pancreatic cancer (adjusted HR: 2.294, 95% CI: 1.267-4.151). The association was found to be more prominent in females and elderly (aged ≥ 60) individuals according to subgroup analyses.</p><p><strong>Conclusions: </strong>pSS was associated with increased risks of colorectal and pancreatic cancers, particularly among females and older adults. Further research should explore the underlying mechanisms and the impact of pSS duration and severity on cancer risk.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145601746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary acetylated protein as a biomarker of lupus nephritis: a prospective cohort study.","authors":"Yeo-Jin Lee, Eun-Ju Lee, Kyunggon Kim, Minji Kim, Ji Young Yu, Minjoong Kim, Soo Min Ahn, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Yong-Gil Kim","doi":"10.1186/s13075-025-03684-8","DOIUrl":"10.1186/s13075-025-03684-8","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"27 1","pages":"220"},"PeriodicalIF":4.6,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12645779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145601731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does perioperative discontinuation of anti-rheumatic drugs increase postoperative complications in orthopedic surgery for rheumatoid arthritis?","authors":"Hiromu Ito, Hajime Ishikawa, Shigeyoshi Tsuji, Masanori Nakayama, Keiichiro Nishida, Takeshi Mochizuki, Kosuke Ebina, Toshihisa Kojima, Takumi Matsumoto, Ayako Kubota, Arata Nakajima, Atsushi Kaneko, Isao Matsushita, Ryota Hara, Koji Sakuraba, Yukio Akasaki, Tsukasa Matsubara, Yuichi Mochida, Katsuaki Kanbe, Natsuko Nakagawa, Koichi Murata, Shigeki Momohara","doi":"10.1186/s13075-025-03683-9","DOIUrl":"https://doi.org/10.1186/s13075-025-03683-9","url":null,"abstract":"This study aimed to investigate whether discontinuation of biological or targeted synthetic antirheumatic disease-modifying drugs (bDMARDs or tsDMARDs) influences the incidence of postoperative complications in patients with rheumatoid arthritis (RA) undergoing orthopedic surgery. A retrospective multicenter cohort study including patients receiving bDMARDs or tsDMARDs who underwent orthopedic surgery was conducted. Data collected encompassed the duration of drug discontinuation and postoperative adverse events, such as delayed wound healing, surgical site infection (SSI), disease flare-ups, and mortality. The association between drug discontinuation and these outcomes was analyzed. Multivariate analyses were conducted to identify potential risk factors for these events. A total of 2,060 cases were initially enrolled. After applying inclusion and exclusion criteria, data from 1,953 patients were analyzed. No significant differences were observed between the groups regarding delayed wound healing, SSI, or mortality. However, the incidence of disease flare-ups was substantially higher in the drug discontinuation group and in the interleukin (IL)-6 inhibitor group. Multivariate analysis identified that tumor necrosis factor α and IL-6 inhibitor use was associated with a higher risk of delayed wound healing relative to T-cell function modifiers. In orthopedic surgery for patients with RA, maintaining the standard or the half of administration interval of bDMARD appears safe in the preoperative period. However, the drug discontinuation may increase the risk of postoperative flare-ups, particularly with IL-6 inhibitors. In addition, T-cell function modifiers may be associated with a lower risk of delayed wound healing, suggesting their safety profile in this context.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"32 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanical growth factor inhibited syndesmophyte formation and the progression of osteoarthritis and ankylosing spondylitis-like symptoms in HLA-B27/Hu-β2m transgenic rats","authors":"Abu Moro, Hongyu Qin, ShuangShuang Yuan, Hao Li, ShiAn Liao, JinSong Yang","doi":"10.1186/s13075-025-03677-7","DOIUrl":"https://doi.org/10.1186/s13075-025-03677-7","url":null,"abstract":"Studies have documented that exercise programs have symptomatic relief benefits for ankylosing spondylitis patients. It has also been reported that MGF (Mechanical/Mechano Growth Factor) and related gene expressions can be stimulated by certain exercises. In this study, we explored the possible role(s) MGF could play in controlling arthritis and ankylosing spondylitis-like symptoms in HLA-B27/Hu-β2m transgenic rats. HLA-B27/ Hu-β2m transgenic rats were inoculated with inactivated Mycobacterium tuberculosis to induce arthritis and ankylosing spondylitis, followed by MGF treatment for seven weeks. The animal models were monitored for the onset, severity, and progression of clinical symptoms. Our results indicated a dose-dependent increase in the time of onset of arthritis symptoms from 14 days in the control group to 23 days in the high-dose MGF group. Our results also indicated a dose-dependent increase in the anti-inflammatory cytokines IL-2 and IL-10 and decrease in the pro-inflammatory cytokine TNF-α in the peripheral circulation and in bony infiltrations. Likewise, there was a dose-dependent inhibition of STAT3 (signal transducer and activator of transcription 3) and RORγt (retinoic acid-related orphan receptor gamma-t) expression, which was further confirmed by the inhibition of IL-17 expression. From the results of our study, it can be concluded that MGF controlled inflammation and inhibited bone erosion and syndesmophyte formation in HLA-B27/Hu-β2m transgenic rats by stimulating IL-2 and IL10 production while downregulating TNF-α, STAT3, RORγt, and IL-17 expression in a dose-dependent manner, leading to a significant reduction in arthritis and AS-like clinical symptoms.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"14 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus","authors":"Vassilis L. Souliotis, Konstantinos Vougas, Vassilis G. Gorgoulis, Petros P. Sfikakis","doi":"10.1186/s13075-025-03689-3","DOIUrl":"https://doi.org/10.1186/s13075-025-03689-3","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Retraction Note: Arthritis Research &amp; Therapy 18, 182 (2016) &lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;https://doi.org/10.1186/s13075-016-1081-3&lt;/b&gt;&lt;/p&gt;&lt;p&gt;The Editors in Chief have retracted this article. In Fig. 2 d, the Rad51 and DAPI panels at 8 h appear to overlap with the “pATM-treated” panels in Fig. 1D in a previously-published article by some of the same authors [1]. Additionally, the HC panels at 24 h in Fig. 2 d appear to overlap with the QSLE panels at 48 h in the same figure, and lanes 5 and 6 in Fig. 4c appear to overlap adjusted for exposure, with lane 6 apparently overlapping with lane RL5 in Fig. 1k in another paper by the same corresponding author that was under submission at the same time [2]. The authors were unable to provide the original images for Fig. 4k; although they did provide images for Fig. 2 d, the editors were unable to verify that these images came from the same experiment. Vassilis L. Souliotis and Petros P. Sfikakis agree to this retraction. Konstantinos Vougas and Vassilis G. Gorgoulis have not replied to correspondence about this retraction.&lt;/p&gt;&lt;ol data-track-component=\"outbound reference\" data-track-context=\"references section\"&gt;&lt;li data-counter=\"1.\"&gt;&lt;p&gt;Stefanou DT, Bamias A, Episkopou H, Kyrtopoulos SA, Likka M, Kalampokas T, et al. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer. PLoS One. 2015;10(2):e0117654. https://doi.org/10.1371/journal.pone.0117654.&lt;/p&gt;&lt;p&gt;Article CAS PubMed PubMed Central Google Scholar &lt;/p&gt;&lt;/li&gt;&lt;li data-counter=\"2.\"&gt;&lt;p&gt;Maria Gkotzamanidou E, Terpos C, Bamia NC, Munshi, Meletios A, Dimopoulos, Vassilis L, Souliotis. DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. Blood. 2016;128(9):1214–25. https://doi.org/10.1182/blood-2016-01-691618.&lt;/p&gt;&lt;p&gt;Article CAS PubMed PubMed Central Google Scholar &lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;Download references&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/p&gt;&lt;h3&gt;Authors and Affiliations&lt;/h3&gt;&lt;ol&gt;&lt;li&gt;&lt;p&gt;Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece&lt;/p&gt;&lt;p&gt;Vassilis L. Souliotis&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Joint Rheumatology Program and First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece&lt;/p&gt;&lt;p&gt;Vassilis L. Souliotis &amp; Petros P. Sfikakis&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Biomedical Research Foundation, Academy of Athens, Athens, Greece&lt;/p&gt;&lt;p&gt;Konstantinos Vougas &amp; Vassilis G. Gorgoulis&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Molecular Carcinogenesis Group, Department of Histology and Embryology, National and Kapodistrian University of Athens Medical School, Athens, Greece&lt;/p&gt;&lt;p&gt;Vassilis G. Gorgoulis&lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;span&gt;Authors&lt;/span&gt;&lt;ol&gt;&lt;li&gt;&lt;span&gt;Vassilis L. Souliotis&lt;/span&gt;View author publications&lt;p&gt;&lt;span&gt;Search author on:&lt;/span&gt;&lt;span&gt;P","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"220 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145545722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omentin-1 reduced synovial M1 macrophages through SIRT6 signaling pathway and alleviated knee osteoarthritis response in mice","authors":"Hao Wu, Weixue Sun, Qian Zhang, Gong Cheng, Zhilin Cao","doi":"10.1186/s13075-025-03680-y","DOIUrl":"https://doi.org/10.1186/s13075-025-03680-y","url":null,"abstract":"This study aimed to evaluate the therapeutic effects of Omentin-1 on osteoarthritis and explore its protective mechanisms. Two osteoarthritis mouse models were created: wild-type and SIRT6−/−. After five weeks of Omentin-1 injection, we evaluated M1 and M2 macrophage distribution in the mouse synovium and measured inflammatory factor levels. Matrix proteins related to cartilage repair were detected, and safranin O-green and toluidine blue staining were used to evaluate the repair. Furthermore, we evaluated how Omentin-1 regulated macrophage polarization and explored potential mechanisms. Omentin-1 was low in osteoarthritis mice and linked to M1 macrophage polarization. It protected these mice by reducing synovial inflammation, decreasing M1 macrophages, increasing M2 macrophages, and lowering pro-inflammatory factors while raising anti-inflammatory factors and minimizing inflammatory cell infiltration in the synovium. Omentin-1 enhanced Collagen II and α-SMA expression in cartilage, aiding repair. Further mechanistic studies indicated that Omentin-1 can enhance the expression of SIRT6 in the joint tissues of mice with osteoarthritis. Omentin-1’s inhibition of inflammation in osteoarthritis mice was linked to SIRT6. Elevated Omentin-1 levels can mitigate the inflammatory response in osteoarthritis by enhancing SIRT6 expression, inhibiting inflammatory factors, suppressing M1 macrophages, and increasing M2 macrophages.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"17 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145535327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated metabolomic profiling identifies citrate as novel diagnostic biomarker for Anti-MDA5-Positive dermatomyositis","authors":"Tianqi Li, Jinlei Sun, Ting Li, Junyao Liu, Yi Cao, Peiling Liu, Cong Wang, Fang Dong, Liangzhi Liu, Wenhui Lou, Shengyun Liu, Yusheng Zhang, Panpan Zhang","doi":"10.1186/s13075-025-03676-8","DOIUrl":"https://doi.org/10.1186/s13075-025-03676-8","url":null,"abstract":"Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5 + DM) is a unique subtype of idiopathic inflammatory myopathy (IIM) with a poorer prognosis. The immune-metabolic landscape underlying anti-MDA5 + DM pathogenesis remains poorly defined. In our study, we integrated metabolomic profiling of plasma and peripheral blood mononuclear cells (PBMCs) in anti-MDA5 + DM. This study enrolled 183 patients with IIM and 104 healthy controls (HCs), comprising a discovery cohort of 150 patients (67 anti-MDA5 + DM patients and 83 anti-MDA5- IIM patients serving as disease controls) and 71 HCs, as well as a validation cohort of 33 patients and 33 HCs. To establish a robust diagnostic model, we implemented a dual analytical approach: seven machine learning algorithms were initially employed to identify key differentially expressed metabolites (DEMs), followed by LASSO regression analysis for optimal feature selection and model construction. Decision curve analysis (DCA) was subsequently conducted to assess their clinical applicability in decision-making scenarios. DHEAS and citrate in plasma were validated using enzyme-linked immunosorbent assay (ELISA) and biochemical assay, respectively. Non-targeted metabolomic profiling of plasma identified 90DEMs distinguishing anti-MDA5 + DM patients from HCs, including 65 upregulated and 25 downregulated metabolites. Pathway enrichment analysis revealed the predominant involvement of these plasma DEMs in beta-alanine metabolism. PBMC-derived targeted metabolomics identified 41 DEMs in anti-MDA5 + DM compared with HCs, comprising 21 upregulated and 20 downregulated metabolites. The DEMs in PBMCs also mainly participated in the beta-alanine metabolism pathway. From these DEMs, DHEAS, citrate, dimethylglycine, histidine, PAGN and Melilotate were identified as candidate biomarkers in anti-MDA5 + DM. Clinically, DHEAS levels showed a negative correlation with the prevalence of rapidly progressive interstitial lung disease (RP-ILD), citrate exhibited a negative association with rash, while dimethylglycine displayed a positive association with mortality and RP-ILD. Further combined analysis showed that the expression of plasma and PBMC dehydroepiandrosterone sulfate (DHEAS) and citrate may serve as reliable diagnostic biomarkers. Finally, DHEAS and citrate exhibited concordant variation patterns in the validation cohort. Our study underscores the pivotal role of DHEAS and citrate as promising diagnostic biomarkers of IIM and anti-MDA5 + DM, respectively, providing novel insights into the pathogenic mechanism and potential therapeutic targets.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"29 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145535330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease","authors":"Shuai Zhu, Shanshan Li, Lipu Shi, Tianshu Chu, Zhenguo Huang, Xin Lu, Guochun Wang, Yongpeng Ge","doi":"10.1186/s13075-025-03675-9","DOIUrl":"https://doi.org/10.1186/s13075-025-03675-9","url":null,"abstract":"Currently, there are only a few effective treatments for anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5) positive dermatomyositis (DM)-associated interstitial lung disease (ILD). The aim of this study was to evaluate the efficacy and safety of baricitinib in patients with MDA5 + DM-ILD. The study was a retrospective cohort design that evaluated patients with MDA5 + DM-ILD who had received or not received baricitinib. Clinical symptoms, laboratory data, and survival were compared in the two groups. Thirty-nine patients with MDA5 + DM-ILD who received baricitinib were included in the study. After baricitinib therapy, 31 patients (79.5%) had a clinical improvement that included Gottron’s sign (p < 0.001), heliotrope rash (p < 0.001), and dyspnea (p = 0.003). The median HRCT score decreased from 115 to 97.5 (p < 0.001), while the FVC improved significantly (76.44% vs. 90.73%, p < 0.001). In addition, serum ferritin levels (739.9 ng/ml vs. 56.3 ng/ml, p < 0.001) and lactate dehydrogenase (LDH) levels (313 U/L vs. 233 U/L, p = 0.003) decreased significantly. Notably, lymphocyte counts increased significantly, CD4 + T cells (354 cells/µl vs. 663 cells/µl, p < 0.001), and CD8 + T cells (180 cells/µl vs. 449 cells/µl, p < 0.001). Furthermore, the glucocorticoid dose reduced significantly from 40 mg daily to 10 mg daily (p < 0.001). Compared with the control group, the baricitinib group had a greater six-month survival (87.2% vs. 70%, p = 0.047). While first-line baricitinib showed a superior survival rate compared to conventional therapy (84.6% vs. 52.9%, p = 0.046). This study indicates that Baricitinib is a potential therapeutic for MDA5 + DM-ILD, reducing LDH and ferritin, ameliorating ILD progression, and improving survival, with first-line use may provide a significant survival advantage. However, larger prospective controlled studies are required to evaluate its efficacy. 1. This is the retrospective cohort study of baricitinib in the treatment of MDA5 + DM-ILD. 2. Baricitinib improve clinical symptoms, reduce LDH and serum ferritin levels, and reduce ILD progression in MDA5 + DM. 3. Baricitinib could improve MDA5 + DM patients’ survival, with first-line use may provide a significant survival advantage.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"92 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial","authors":"Eugen Feist, Michael E. Luggen, Evgeny L. Nasonov, Sergey S. Yakushin, Daria V. Bukhanova, Alina N. Egorova, Sergey A. Grishin, Mikhail Y. Samsonov, Josef S. Smolen","doi":"10.1186/s13075-025-03682-w","DOIUrl":"https://doi.org/10.1186/s13075-025-03682-w","url":null,"abstract":"Patients with rheumatoid arthritis (RA) have an increased prevalence of comorbidities, which is associated with higher RA disease activity and worse disease outcomes. The aim of this analysis was to evaluate the impact of the comorbidity burden on the efficacy of the IL-6 inhibitor olokizumab (OKZ) and the tumour necrosis factor (TNF) inhibitor adalimumab (ADA) in the CREDO-2 randomized controlled clinical trial cohort of patients with active RA. A total of 1402 patients with RA were included in the analysis and divided into two groups on the basis of the modified Charlson Comorbidity Index (mCCI) at baseline: those having no comorbid conditions, NCC (mCCI = 1; RA only) vs. those having comorbid conditions, CC (mCCI ≥ 2; RA and ≥ 1 comorbidity). The key outcomes at Week (W) 24 were the proportions of patients with CDAI ≤ 10 and CDAI ≤ 2.8, other outcomes were ACR50 (W12, W24), proportions of patients with SDAI ≤ 3.3 (W24). All groups had similar proportions of approximately 25% of patients with mCCI ≥ 2. There was no significant difference in efficacy between the OKZ q4w or q2w-treated NCC and CC groups at 3 and 6 months of treatment. The same was observed for the placebo group. In contrast, comorbidities reduced CDAI ≤ 10 and ACR50 outcomes upon ADA treatment at 6 months. This post hoc analysis of the phase III CREDO-2 study suggests that the presence of at least one CCI comorbidity, including common disorders such as chronic pulmonary diseases and cardiovascular diseases, does not affect the OKZ treatment results in RA patients. In contrast, comorbidities reduce several efficacy outcomes upon ADA treatment at 6 months. The CCI was not associated with placebo group results and had no influence on safety outcomes. NCT02760407 submitted 2016-05-02.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"87 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of MRI slice thickness on the detection of spinal syndesmophytes in axial spondyloarthritis","authors":"Kalliopi Klavdianou, Daniel Benjamin Abrar, Alexander Dieter Mewes, Styliani Tsiami, Philipp Sewerin, Xenofon Baraliakos","doi":"10.1186/s13075-025-03665-x","DOIUrl":"https://doi.org/10.1186/s13075-025-03665-x","url":null,"abstract":"Radiography is commonly used in clinical practice for detecting syndesmophytes in radiographic axial Spondyloarthritis (r-axSpA), while the ability of magnetic resonance imaging (MRI) to detect such bony structures is questionable due to its slicing technique. We aimed to assess the ability and performance for detection of syndesmophytes on MRI using different slice thicknesses and compare them with radiography in r-axSpA. MRI (T1-weighted (T1W) sequences) with slice thicknesses of 1–6 mm of the lower thoracic and lumbar spine were prospectively performed in patients with available radiographs. Each vertebral corner (VC) (anterior and posterior) from thoracic (Th11) to lumbar (L5) was assessed for presence/absence of syndesmophytes and/or fat lesions (FL, MRI only) by two experienced readers in independent MRI and radiography sessions and agreement was then reached in consensus. A total of 1.204 VCs were assessed from 43 r-axSpA patients. Syndesmophytes were recorded in 19.3% VCs on radiography and in 38.3%, 37.5%, 34.8%, 33.7%, 31.4%, 28.7% VCs on MRI slice thicknesses of 1–6 mm, respectively (all p ≤ 0.001 vs. radiography). Although more syndesmophytes were recorded on MRI than radiography, MRI also missed 21%-31.3% syndesmophytes detected in radiography. Agreement with radiography was found in 72.6%, 73.8%, 75.9%, 76%, 77.3% and 78.5% on MRI slice thicknesses of 1–6 mm, respectively. FL were detected in 38.2%-39.2% in slice thicknesses 1–6 mm. Occurrence of FL was associated with better agreement between MRI and radiography findings. The thinner the MRI slices, the more syndesmophytes were detected compared to radiography, but the best agreement with radiography was found in the thicker slices. The presence of fat lesions on MRI was associated with better agreement with radiography for syndesmophyte detection.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"143 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}